Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAT1 | P18440 | 6/20 | 1.00 |
| ▸ | PIM1 | P11309 | 4/20 | 0.68 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.66 |
| ▸ | GSK3B | P49841 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | MYC | P01106 | 2/20 | 0.63 |
| ▸ | MAX | P61244 | 2/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15421702 | 1.00 | NAT1 (1.00) | NAT1PIM1PTP4A3GSK3BTDP1 | |
| SCHEMBL3425971 | 1.00 | NAT1 (1.00) | NAT1PIM1PTP4A3GSK3BTDP1 | |
| SCHEMBL18103072 | 0.88 | NAT1 (0.79) | NAT1PIM1PTP4A3GSK3BMYC | |
| SCHEMBL18102942 | 0.88 | NAT1 (0.78) | NAT1PIM1PTP4A3GSK3BTDP1 | |
| SCHEMBL1449166 | 0.85 | NAT1 (0.74) | NAT1PIM1PTP4A3MYCMAX | |
| SCHEMBL18102951 | 0.85 | NAT1 (0.74) | NAT1PIM1PTP4A3GSK3BMYC | |
| SCHEMBL18102866 | 0.85 | NAT1 (0.73) | NAT1PIM1PTP4A3GSK3BMYC | |
| SCHEMBL1249158 | 0.84 | NAT1 (1.00) | NAT1PIM1GSK3BTDP1 | |
| SCHEMBL1249157 | 0.84 | NAT1 (1.00) | NAT1PIM1GSK3BTDP1 | |
| SCHEMBL14564270 | 0.84 | NAT1 (1.00) | NAT1PIM1GSK3BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160102065-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2016-04-14 | — | — | US | claimed |
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | UNIVERSITY OF MIAMI (US) | 2019-12-10 | — | — | US | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| US-9896421-B2 | Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use thereof | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2018-02-20 | — | — | US | disclosed |
| WO-2016154255-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | UNIVERSITY OF MIAMI (US) | 2016-09-29 | — | — | WO | disclosed |
| US-20160102065-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2016-04-14 | — | — | US | disclosed |
| US-9216148-B2 | Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use therefor | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2015-12-22 | — | — | US | disclosed |
| WO-2015018797-A2 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2015-02-12 | — | — | WO | disclosed |
| US-20140023603-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2014-01-23 | — | — | US | disclosed |
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | UNIVERSITE LAVAL (CA) | 2009-11-05 | — | — | US | disclosed |
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | UNIVERSITE LAVAL (CA) | 2009-11-05 | — | — | US | disclosed |
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | UNIVERSITE LAVAL (CA) | 2009-11-05 | — | — | US | disclosed |
| WO-2009097695-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | CHLORION PHARMA, INC. (CA) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097695-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | CHLORION PHARMA, INC. (CA) | 2009-08-13 | — | — | WO | disclosed |
| WO-2000018748-A1 | RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | ROCHE DIAGNOSTICS GMBH (DE) | 2000-04-06 | — | — | WO | disclosed |
| EP-0915090-A1 | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1999-05-12 | — | — | EP | disclosed |
| US-5661168-A | ADMINISTERING RHODANINE DERIVATIVES TO CONTROL DIABETES | ELI LILLY AND COMPANY (US) | 1997-08-26 | — | — | US | disclosed |
| US-5523314-A | RHODANINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0587377-A2 | Thiazolidinone derivatives as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1994-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | OPRL1, OPRK1, AHR | NAT1 80/4885PIM1 3687/4885PTP4A3 1188/4885 |
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | NOTCH1, CBFB, HES1 | NAT1 867/4885PIM1 2196/4885PTP4A3 4245/4885 |
| US-20140023603-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR | PPARG, PPARA, PPARD | NAT1 100/4885PIM1 3515/4885PTP4A3 2762/4885 |
| US-20160102065-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF | PPARG, PPARA, TYR | NAT1 60/4885PIM1 3858/4885PTP4A3 2231/4885 |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NOTCH1, CBFB, HES1 | NAT1 867/4885PIM1 2196/4885PTP4A3 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.